Ceretype Neuromedicine, Inc. is a development-stage company applying its revolutionary, AI-based fMRI brain biomarker technologies to improve drug discovery and patient care. Through its unique ability to sub-type and classify the human brain on a neurobiological level, the Company offers novel, precise, biologically-based diagnostic and therapeutic strategies to address psychiatric illness and central nervous system disorders, fundamentally transforming the field of mental health. Based in Cambridge Massachusetts, Ceretype is founded on seminal scientific discoveries made in the laboratory of Drs. Emily Stern, David Silbersweig and Hong Pan at Brigham and Women’s Hospital/Harvard Medical School (BWH/HMS). Prior to its launch, Ceretype’s founders spent the previous decade at BWH/HMS discovering, refining and patenting its key underlying technologies. The Company launched its initial operations in February 2020 upon its CEO’s separation from BWH/HMS.